A detailed history of Geode Capital Management, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,502,698 shares of ERAS stock, worth $11.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,502,698
Previous 3,311,891 35.96%
Holding current value
$11.2 Million
Previous $7.82 Million 57.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.17 - $3.28 $2.58 Million - $3.91 Million
1,190,807 Added 35.96%
4,502,698 $12.3 Million
Q2 2024

Aug 09, 2024

BUY
$1.79 - $2.63 $2.54 Million - $3.74 Million
1,420,348 Added 75.09%
3,311,891 $7.82 Million
Q1 2024

May 13, 2024

BUY
$1.67 - $2.55 $132,985 - $203,061
79,632 Added 4.39%
1,891,543 $3.9 Million
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.49 $161,185 - $240,329
96,518 Added 5.63%
1,811,911 $3.86 Million
Q3 2023

Nov 13, 2023

BUY
$1.97 - $2.91 $197,386 - $291,570
100,196 Added 6.2%
1,715,393 $3.38 Million
Q2 2023

Aug 11, 2023

BUY
$2.57 - $3.3 $234,299 - $300,851
91,167 Added 5.98%
1,615,197 $4.46 Million
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $816,544 - $1.32 Million
298,009 Added 24.31%
1,524,030 $4.59 Million
Q4 2022

Feb 13, 2023

BUY
$3.89 - $8.57 $299,627 - $660,104
77,025 Added 6.7%
1,226,021 $5.28 Million
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $2.18 Million - $4 Million
374,638 Added 48.38%
1,148,996 $8.96 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $8.72 $235,086 - $447,588
51,329 Added 7.1%
774,358 $4.31 Million
Q1 2022

May 13, 2022

BUY
$8.6 - $15.48 $2.8 Million - $5.03 Million
325,202 Added 81.74%
723,029 $6.22 Million
Q4 2021

Feb 11, 2022

BUY
$12.51 - $22.75 $269,052 - $489,284
21,507 Added 5.72%
397,827 $6.2 Million
Q3 2021

Nov 12, 2021

BUY
$17.43 - $24.34 $6.56 Million - $9.16 Million
376,320 New
376,320 $7.99 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $304M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.